Kerala Ayurveda Ltd

Kerala Ayurveda’s shares reached a fresh 52-week low of Rs.301.35 today, marking a significant decline amid ongoing financial pressures and subdued market performance. The stock has been under pressure for the past two sessions, reflecting challenges in the company’s financial health and market sentiment.

Kerala Ayurveda, a microcap player in the Pharmaceuticals & Biotechnology sector, has undergone a revision in its market evaluation reflecting shifts in its financial health and technical outlook. This adjustment highlights ongoing challenges in the company’s fundamentals and market positioning, prompting investors to reassess its prospects amid sector dynamics.

Kerala Ayurveda, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently formed a Death Cross, a technical pattern where the 50-day moving average crosses below the 200-day moving average. This development often signals a shift towards a bearish trend and suggests a weakening momentum in the stock’s price trajectory.

Kerala Ayurveda Ltd., a micro-cap pharmaceutical company specialising in Ayurvedic products and wellness services, reported a consolidated net loss of ₹6.34 crores for Q2 FY26, a sharp deterioration from a profit of ₹1.99 crores in Q1 FY26. The quarter-on-quarter decline of 418.59% and year-on-year plunge of 285.38% underscore mounting operational pressures that have eroded profitability despite modest revenue growth. The company's market capitalisation stands at ₹470.00 crores, with shares trading at ₹385.00 as of November 18, 2025.

Kerala Ayurveda, a microcap in the Pharmaceuticals & Biotechnology sector, has seen its stock price rise slightly amid market volatility. The company has delivered impressive long-term returns compared to the Sensex, although it has underperformed in the short term. Current technical indicators present mixed signals regarding its market position.

Kerala Ayurveda, a microcap in the Pharmaceuticals & Biotechnology sector, has experienced notable stock fluctuations, with a 52-week high of 625.00 and a low of 250.00. The company has shown impressive long-term growth, significantly outperforming the Sensex over one, three, and five-year periods.

Kerala Ayurveda, a microcap in the Pharmaceuticals & Biotechnology sector, has shown resilience with a 50.43% return over the past year, significantly outperforming the Sensex. Recent evaluations reflect mixed technical indicators, with varying trends across weekly and monthly analyses, underscoring the company's strong market position.

Kerala Ayurveda, a microcap in the Pharmaceuticals and Biotechnology sector, has recently revised its stock evaluation amid changing market conditions. The stock has shown impressive long-term growth, outperforming the Sensex over one, three, and five years, indicating its resilience and potential in a challenging environment.